HighTide Therapeutics (HKG:2511) completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate (HTD1801), for the treatment of patients with type 2 diabetes mellitus.
The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.
Final data from the trial is expected to come out in 2025, the filing said.
Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。